SubsidieMeestersCommercialisation and scale up of a Vaginal Microbiome Screening service with a menstrual tampon collection device and a digital layer to provide diagnosis, disease risk evaluation and aftercare.
VMS is a home-based gynaecological test kit that uses tampons for accurate STI and HPV screening, offering comprehensive aftercare and insights into vaginal health.
Projectdetails
Introduction
VMS is a home-based gynaecological test kit, using a menstrual tampon for sample collection. VMS will improve the accuracy and convenience with which STI, vaginal infections, and HPV screening is undertaken.
Technology and Innovation
Daye has patented the proprietary protocol for DNA extraction from a tampon for PCR analysis, testing for 16 different factors at a time. VMS can be used to detect:
- Vaginal dysbiosis
- HPV
- STIs, such as chlamydia, gonorrhea, and trichomoniasis
Benefits of VMS
Vaginal microbiome screening with VMS will unlock invaluable insights into our customers’ vaginal health. There’s a direct correlation between vaginal microbiome health and the likelihood of:
- Contracting an STI
- Developing a gynecological cancer
- Experiencing fertility and pregnancy challenges
- Susceptibility to recurrent vaginal and urethral infections
Aftercare Services
Post-screen, VMS will offer comprehensive aftercare, including:
- Prescriptions
- Doctor consultations
- Booking in-person visits
- Vaginal microbiome enhancement plan with probiotics
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.499.999 |
| Totale projectbegroting | € 3.794.918 |
Tijdlijn
| Startdatum | 1-7-2023 |
| Einddatum | 30-6-2025 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- TAMPONENI INOVATSII OODpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Breakthrough dual-action OTC tablet for treatment and prevention of both bacterial and fungal vaginitisGedea aims to commercialize pHyph, an antimicrobial-free pessary for treating and preventing BV and VVC, addressing a significant medical need while avoiding antibiotic resistance. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Translational Microbiome PlatformMICK is a digital decision support system that automates microbiome analysis for healthcare professionals, reducing costs by 75% and speeding up turnaround times for clinical applications. | EIC Accelerator | € 2.156.681 | 2022 | Details |
Transforming Molecular Diagnostics through NanoTechnologyAltratech Ltd aims to revolutionize molecular diagnostics by using patented nanotechnology for rapid, non-clinical detection of viruses and pathogens without biological amplification. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Hormone-free solution for vaginal atrophyAVeta is a hormone-free medical device providing safe, affordable, and effective self-administered therapy for women suffering from vaginal atrophy, enhancing their quality of life. | EIC Accelerator | € 2.500.000 | 2022 | Details |
Fast, easy diagnostics for personalised phage therapyVésale Bioscience's Phagogram is an automated diagnostic tool that rapidly identifies effective bacteriophages for personalized phage therapy, reducing testing time from days to hours. | EIC Accelerator | € 1.800.000 | 2023 | Details |
Breakthrough dual-action OTC tablet for treatment and prevention of both bacterial and fungal vaginitis
Gedea aims to commercialize pHyph, an antimicrobial-free pessary for treating and preventing BV and VVC, addressing a significant medical need while avoiding antibiotic resistance.
Translational Microbiome Platform
MICK is a digital decision support system that automates microbiome analysis for healthcare professionals, reducing costs by 75% and speeding up turnaround times for clinical applications.
Transforming Molecular Diagnostics through NanoTechnology
Altratech Ltd aims to revolutionize molecular diagnostics by using patented nanotechnology for rapid, non-clinical detection of viruses and pathogens without biological amplification.
Hormone-free solution for vaginal atrophy
AVeta is a hormone-free medical device providing safe, affordable, and effective self-administered therapy for women suffering from vaginal atrophy, enhancing their quality of life.
Fast, easy diagnostics for personalised phage therapy
Vésale Bioscience's Phagogram is an automated diagnostic tool that rapidly identifies effective bacteriophages for personalized phage therapy, reducing testing time from days to hours.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Disease and vaccine monitoring based on non-invasive genital tract liquid biopsy sampling.URISAMP aims to validate first-void urine as a non-invasive alternative to cervical samples for monitoring HPV-related immune responses, enhancing STI vaccine research and diagnostics. | ERC Starting... | € 1.499.265 | 2022 | Details |
Femiscope voor zelfonderzoekHet project ontwikkelt een Femiscope totaalconcept voor zelfonderzoek in de gynaecologie, gericht op het verbeteren van zorgefficiëntie en kwaliteit via TeleMedicine. | Mkb-innovati... | € 289.677 | 2016 | Details |
She Sense: an accurate and non-invasive test that enables simpler, earlier and more cost-effective diagnosis of patients with endometriosisThe project aims to advance the She Sense test for non-invasive endometriosis diagnosis by optimizing its digital biomarker and validating it clinically for commercial readiness. | EIC Transition | € 2.499.166 | 2023 | Details |
Deciphering female’s SEx hormones - MIcrobiota interactions during a menstrual CYCLE for an efficient personalized medicine in cardiometabolic disordersThe SEMICYCLE project aims to identify female-specific microbiota features influencing glycaemic and lipid metabolism to improve prevention and treatment strategies for cardiometabolic disorders in women. | ERC Starting... | € 1.499.286 | 2023 | Details |
Rapid Affordable Microbiota Analysis at the point of NeedBforCure's RAMAN project aims to develop a rapid, affordable microbiota analysis device for point-of-need testing, enhancing health and production outcomes in various sectors. | EIC Transition | € 2.466.223 | 2024 | Details |
Disease and vaccine monitoring based on non-invasive genital tract liquid biopsy sampling.
URISAMP aims to validate first-void urine as a non-invasive alternative to cervical samples for monitoring HPV-related immune responses, enhancing STI vaccine research and diagnostics.
Femiscope voor zelfonderzoek
Het project ontwikkelt een Femiscope totaalconcept voor zelfonderzoek in de gynaecologie, gericht op het verbeteren van zorgefficiëntie en kwaliteit via TeleMedicine.
She Sense: an accurate and non-invasive test that enables simpler, earlier and more cost-effective diagnosis of patients with endometriosis
The project aims to advance the She Sense test for non-invasive endometriosis diagnosis by optimizing its digital biomarker and validating it clinically for commercial readiness.
Deciphering female’s SEx hormones - MIcrobiota interactions during a menstrual CYCLE for an efficient personalized medicine in cardiometabolic disorders
The SEMICYCLE project aims to identify female-specific microbiota features influencing glycaemic and lipid metabolism to improve prevention and treatment strategies for cardiometabolic disorders in women.
Rapid Affordable Microbiota Analysis at the point of Need
BforCure's RAMAN project aims to develop a rapid, affordable microbiota analysis device for point-of-need testing, enhancing health and production outcomes in various sectors.